An analysis of cost-saving in the German statutory health insurance system due to the introduction of epoetin alfa biosimilars in Germany. - Raitner I; Müller B; Vijayan A; Zimmermann L; Bramlage P; Ness NH; Müller M (Frontiers in public health, 2025)